53 related articles for article (PubMed ID: 25299893)
1. First PI3k inhibitor launches into crowded hematology markets.
Morrison C
Nat Biotechnol; 2014 Oct; 32(10):963-4. PubMed ID: 25299893
[No Abstract] [Full Text] [Related]
2. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
3. Idelalisib has activity in mantle cell lymphoma.
Cancer Discov; 2014 May; 4(5):OF8. PubMed ID: 24795031
[TBL] [Abstract][Full Text] [Related]
4. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2015 Oct; 373(16):1580-2. PubMed ID: 26466009
[No Abstract] [Full Text] [Related]
5. [CAL-101,a novel agent of targeted therapy in hematological malignancies].
Li CJ; Zhang Q; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):530-3. PubMed ID: 24763037
[TBL] [Abstract][Full Text] [Related]
6. More on Merkel-Cell Carcinoma.
Blom A; Saiag P
N Engl J Med; 2016 Feb; 374(5):494-5. PubMed ID: 26840149
[No Abstract] [Full Text] [Related]
7. More on Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2016 Feb; 374(5):495. PubMed ID: 26840148
[No Abstract] [Full Text] [Related]
8. NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies.
J Natl Compr Canc Netw; 2016 Mar; 14(3):xl. PubMed ID: 27396030
[No Abstract] [Full Text] [Related]
9. A slowly developed severe cutaneous adverse reaction to idelalisib.
Huilaja L; Lindgren O; Soronen M; Siitonen T; Tasanen K
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e192-e193. PubMed ID: 29150880
[No Abstract] [Full Text] [Related]
10. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
11. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ; Furman M; Winer ES
Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
[TBL] [Abstract][Full Text] [Related]
12. Putative roles for PI3K α and δ isoforms in refractory mantle cell lymphoma.
Jessen KA; Lannutti BJ
Acta Haematol; 2014; 131(4):218-9. PubMed ID: 24296619
[No Abstract] [Full Text] [Related]
13. PI3K-δ inhibitor produces long-lasting responses.
Cancer Discov; 2013 Jul; 3(7):OF11. PubMed ID: 23847354
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide 3-kinase α inhibitors: a patent review.
Denny WA
Expert Opin Ther Pat; 2013 Jul; 23(7):789-99. PubMed ID: 23488930
[TBL] [Abstract][Full Text] [Related]
15. Beta-testing of PI3-kinase inhibitors: is beta better?
Shepherd PR; Denny WA
Cancer Discov; 2012 May; 2(5):393-4. PubMed ID: 22588874
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.
Stec MM; Andrews KL; Booker SK; Caenepeel S; Freeman DJ; Jiang J; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Yang K; Zalameda LP; Zhang N; Hughes PE; Norman MH
J Med Chem; 2011 Jul; 54(14):5174-84. PubMed ID: 21714526
[TBL] [Abstract][Full Text] [Related]
17. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
Fruman DA; Rommel C
Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
[TBL] [Abstract][Full Text] [Related]
18. A practical drug discovery project at the undergraduate level.
Fray MJ; Macdonald SJ; Baldwin IR; Barton N; Brown J; Campbell IB; Churcher I; Coe DM; Cooper AW; Craven AP; Fisher G; Inglis GG; Kelly HA; Liddle J; Maxwell AC; Patel VK; Swanson S; Wellaway N
Drug Discov Today; 2013 Dec; 18(23-24):1158-72. PubMed ID: 24051399
[TBL] [Abstract][Full Text] [Related]
19. PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.
Cushing TD; Metz DP; Whittington DA; McGee LR
J Med Chem; 2012 Oct; 55(20):8559-81. PubMed ID: 22924688
[No Abstract] [Full Text] [Related]
20. Medicinal chemistry of dihydropyran-based medium ring macrolides related to aspergillides: selective inhibition of PI3Kα.
Lambu MR; Kumar S; Yousuf SK; Sharma DK; Hussain A; Kumar A; Malik F; Mukherjee D
J Med Chem; 2013 Aug; 56(15):6122-35. PubMed ID: 23845251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
